Status:
Concluded without agreement
Manufacturer:
KYE Pharmaceuticals Inc.
Indication:
Angina Pectoris
Last updated January 23, 2023
Status:
Concluded with an LOI
Manufacturer:
Knight Therapeutics Inc.
Indication:
Postmenopausal dyspareunia, moderate to severe
Last updated January 20, 2023
Status:
Concluded with an LOI
Manufacturer:
Medexus Pharmaceuticals, Inc.
Indication:
Pediatric chronic severe drooling reduction (neurologic)
Last updated January 16, 2023
Status:
Concluded with an LOI
Manufacturer:
Valeo Pharma Inc.
Indication:
Parkinson's disease
Last updated January 16, 2023
Elonox and Elonox HP (enoxaparin sodium)
Status:
Concluded with an LOI
Manufacturer:
Fresenius Kabi Canada Ltd.
Indication:
Thrombosis and cardiovascular conditions (prevention or treatment)
Last updated January 9, 2023
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Urothelial carcinoma (UC), monotherapy for the adjuvant treatment of adult patients who are at high risk of recurrence after undergoing radical resection of UC
Last updated December 23, 2022
Status:
Concluded without agreement
Manufacturer:
Merz Therapeutics Canada
Indication:
Chronic Sialorrhea associated with neurological disorders
Last updated December 23, 2022
Status:
Concluded with an LOI
Manufacturer:
BeiGene, Ltd.
Indication:
Waldenström's Macroglobulinemia
Last updated December 22, 2022
Status:
Concluded without agreement
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated December 20, 2022
Status:
Negotiations were not pursued
Manufacturer:
AbbVie Corporation
Indication:
Bipolar Disorder
Last updated December 16, 2022